Apotex FDA Thursday, April 30, 2026 0.00 Neutral

FDA Approves SITAGLIPTIN AND METFORMIN HYDROCHLORIDE — Apotex Corp.

# FDA Approves Generic Sitagliptin and Metformin Hydrochloride Combination Apotex Corp. received FDA approval for its generic sitagliptin and metformin hydrochloride combination tablet, expanding competitive options in the diabetes treatment market and potentially lowering costs for patients managing type 2 diabetes. The oral formulation approval is expected to increase price competition in the combination antidiabetic segment, benefiting payers and patients while pressuring branded alternatives.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day